Anzeige
+++Uran durchbricht die 90-Dollar-Marke: – wird Myriad der nächste Uran-Gigant aus Wyoming? – wird Myriad der nächste Uran-Gigant aus Wyoming?+++
PortfolioPlus
Portfolio-Tracker – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
EQS-News

Change in the Management Board 25.08.2026, 19:30 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
O3 Hldg 8,603 % bis 10/29 68,00 % ±0,00 % Frankfurt

EQS-News: O3 Holding GmbH / Key word(s): Personnel
Change in the Management Board

25.08.2026 / 19:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


O3 Holding GmbH - Change in the Management Board

 

BEXBACH, GERMANY – 24th August 2026 – O3 Holding GmbH (the Company), the holding company of KD Pharma Group, announces today the appointment of Manja Boerman as Chief Executive Officer of KD Pharma Group, effective August 24, 2026.

 

Manja brings more than 20 years of international leadership experience in the pharmaceutical, biotechnology, and life sciences industries. Throughout her career, she has successfully led global organizations, built high-performing leadership teams, driven transformational growth, and overseen complex international operations across research, development, manufacturing, and commercialization. She has held CEO and President positions at several leading companies, including Catalent Pharma Solutions, Aesica Pharmaceuticals, Patheon Biologics, Kiadis Pharma, DSM Pharmaceutical Products and most recently served as interim CEO of Prothya Biosolutions. She also serves on the boards of several international life sciences companies.

 

The company thanks Adam Ismail and Thomas Strauch for their excellent leadership during the past months as interim Co-Chief Executive Officers and their work to improve the position of the Company. Adam and Thomas will continue in their respective roles as Chief Commercial Officer and Chief Financial Officer.

 

“We are confident that Manja's leadership, strategic vision, and extensive industry expertise will help accelerate KD Pharma Group's continued growth and strengthen our position as a global leader in our industry,” said Adam Ismail. “Manja’s experience will be invaluable in helping continue the Company’s move to a solid financial position in the wake of a turbulent industry environment,” added Thomas Strauch.

 

“The KD Pharma Group is a respected leader in the omega-3 lipids field with a tremendous heritage of technological innovation, so I am honored to help lead the company into its next phase of growth,” commented Manja Boerman.

 

ABOUT KD PHARMA GROUP

The KD Pharma Group is a CDMO that creates health solutions in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer Omega-3 fatty acids for the pharmaceutical and nutraceutical markets, formulation and encapsulation services, with over 700 employees and a presence in the UK, Norway, Germany, Switzerland, Canada, Peru and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit www.kdpharmagroup.com to learn more.

 

 

IMPORTANT INFORMATION

This release contains forward-looking statements. These statements are based on plans, estimates and projections currently available to KD Pharma Group. Forward-looking statements therefore speak only as of the date they are made. KD Pharma Group assumes no obligation to update or develop such statements in light of new information or future events. By their nature, forward-looking statements involve risks and uncertainties. A variety of important factors could cause actual results to differ materially from those in forward-looking statements.



25.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: O3 Holding GmbH
Am Kraftwerk 6
66450 Bexbach
Germany
Phone: +49 (0)68 26 97 97 00
E-mail: investor.relations@kdpharmagroup.com
Internet: https://kdpharmagroup.com
ISIN: NO0013360552
WKN: A383V0
Listed: Regulated Unofficial Market in Frankfurt
LEI Code: 529900Y5PUIBWBPAQV20
EQS News ID: 2388606

 
End of News EQS News Service

2388606  25.08.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Ihre Lieblingsaktie geschenkt

BörsenNEWS.de und Smartbroker+ starten gemeinsam eine exklusive Bonus-Aktion. Eröffnen Sie bis 31.08.2026 ein Depot bei Smartbroker+ und erhalten als Willkommensgeschenk einen Anteil ausgewählter Aktien im Wert von 50 Euro!.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer